Ascendis Pharma (ASND) Company Report

Analyst Coverage

Research analysts who have asked questions during Ascendis Pharma earnings calls.

Gavin Clark-Gartner

Evercore ISI

7 questions for ASND

Also covers: ACRS, ARGX, CMPS +12 more

Jessica Fye

JPMorgan Chase & Co.

7 questions for ASND

Also covers: ALKS, ALNY, AMRN +23 more

Tazeen Ahmad

Bank of America

7 questions for ASND

Also covers: ACAD, ALNY, APLS +22 more

Derek Archila

Wells Fargo

6 questions for ASND

Also covers: APLS, ARGX, ARVN +11 more

Leland Gershell

Oppenheimer & Co. Inc.

6 questions for ASND

Also covers: ARGX, CAPR, CASI +13 more

Paul Choi

Goldman Sachs

6 questions for ASND

Also covers: AMRN, ARVN, BBIO +13 more

David Lebowitz

Citigroup Inc.

5 questions for ASND

Also covers: ALNY, ARWR, BPMC +11 more

Luca Issi

RBC Capital Markets

5 questions for ASND

Also covers: ADVM, ALLO, ALNY +13 more

Yaron Werber

TD Cowen

5 questions for ASND

Also covers: ALEC, AMGN, ARGX +15 more

Ellie Merle

UBS Group AG

4 questions for ASND

Also covers: ALNY, ALT, ARVN +12 more

Joseph Schwartz

Oppenheimer

4 questions for ASND

Also covers: AUPH, BMRN, CRNX +14 more

Li Wang Watsek

Cantor Fitzgerald

4 questions for ASND

Also covers: AFMD, ALXO, ARVN +7 more

Alex Thompson

Stifel Financial Corp.

3 questions for ASND

Also covers: ARGX, CRNX, IMVT +3 more

Daniel Bronder

Cantor Fitzgerald

3 questions for ASND

Also covers: ARVN, CRIS, RCUS

Maxwell Skor

H.C. Wainwright & Co.

3 questions for ASND

Also covers: AVIR, CRNX, CYTK +4 more

Alexander Thompson

Stifel

2 questions for ASND

Also covers: ACRS, ARGX, CRNX +5 more

Dingding Shi

Jefferies

2 questions for ASND

Also covers: ADCT, AUTL, INCY +6 more

Faisal Khurshid

Leerink Partners

2 questions for ASND

Also covers: ABCL, ANIP, GERN +7 more

Kalpit Patel

B. Riley Securities

2 questions for ASND

Also covers: DERM, EXEL, FBRX +8 more

Kelly Shi

Jefferies

2 questions for ASND

Also covers: ADCT, AGEN, ALDX +17 more

Vikram Purohit

Morgan Stanley

2 questions for ASND

Also covers: ABSI, ARGX, ARQT +11 more

Yun Zhong

Wedbush Securities

2 questions for ASND

Also covers: MNKD, MRKR, PASG +2 more

Eliana Merle

UBS

1 question for ASND

Also covers: ALNY, APLS, ARVN +17 more

Heidi Jacobson

Leerink Partners

1 question for ASND

Joori Park

Leerink Partners

1 question for ASND

Also covers: PTGX

Jose Lora

Jefferies

1 question for ASND

Also covers: HRTX

Kyuwon Choi

Goldman Sachs

1 question for ASND

Also covers: AMRN, BHVN, CYTK +9 more

Simona Stan

Wells Fargo

1 question for ASND

Yun Zheng

Woodbush

1 question for ASND

Latest news

Recent press releases and 8-K filings for ASND.

Ascendis Pharma A/S Reports Strong Revenue Growth in 2025 Driven by YORVIPATH Sales, Continues Strategic Collaborations

ASND

Earnings

Revenue Acceleration/Inflection

New Projects/Investments

**Ascendis Pharma A/S reported a significant increase in revenue to €720.1 million for the year ended December 31, 2025, up from €363.6 million in the prior year, primarily driven by global sales of YORVIPATH®. **
**Despite the revenue growth, the company recorded a net loss of €228.0 million for FY 2025, an improvement from a net loss of €378.1 million in FY 2024, with basic earnings per share of (€3.76). **
**Commercial product revenue for YORVIPATH® surged to €477.4 million in 2025 from €28.7 million in 2024, while SKYTROFA® revenue also increased to €206.2 million. **
**The company maintained a strong liquidity position with cash and cash equivalents of €616.0 million as of December 31, 2025, and saw cash flows from operating activities improve to €53.9 million for the year. **
**Strategic developments include the ongoing collaboration with Novo Nordisk, the commercial launch of YORVIPATH in Japan via Teijin Limited in November 2025, and VISEN Pharmaceuticals' IPO in March 2025, which generated a non-cash gain of €35.7 million for Ascendis Pharma A/S. **

4 days ago

6-K

Ascendis Pharma Reports Q4 and Full-Year 2025 Financial Results

ASND

Earnings

Guidance Update

Share Buyback

Ascendis Pharma reported Q4 2025 product revenue of €240 million and full-year 2025 product revenue of €684 million, with a Q4 2025 operating profit of €10 million.
The company recorded a net loss of €34 million for Q4 2025 and a full-year 2025 net loss of €228 million, or €(3.76) per share.
YORVIPATH revenue totaled €187 million for Q4 2025 and €477 million for the full year 2025, while SKYTROFA revenue was €53 million for Q4 2025 and €206 million for the full year 2025.
As of December 31, 2025, Ascendis Pharma held a cash balance of €616 million. The company expects to generate approximately €500 million in operating cash flow in 2026 and aims for at least €5 billion in global annual product revenue by 2030.
TransCon CNP is under FDA Priority Review with a PDUFA action goal date of February 28, 2026 , and SKYTROFA received FDA approval for adult growth hormone deficiency label expansion in July 2025. The company also plans to initiate a $120 million share repurchase program in 2026.

Feb 11, 2026, 9:50 PM

6-K

Ascendis Pharma Reports Q4 and Full-Year 2025 Financial Results, Provides 2026 and 2030 Outlook

ASND

Earnings

Guidance Update

Product Launch

Ascendis Pharma reported total revenue of EUR 248 million for Q4 2025 and EUR 720 million for the full year 2025, with Europat contributing EUR 187 million and SKYTROFA EUR 53 million in Q4. The company ended 2025 with EUR 616 million in cash and cash equivalents.
The company expects operating cash flow of around EUR 500 million in 2026 and aspires to achieve at least EUR 5 billion in annual product revenue by 2030.
The NDA for TransCon CNP in children with achondroplasia is under review in the US with a PDUFA date of February 28. Europat continues its global expansion, with full commercial launches expected in 10 additional new countries in 2026.

Feb 11, 2026, 9:30 PM

Transcript

Ascendis Pharma Reports Strong Q4 and Full-Year 2025 Financial Results, Provides 2026 and 2030 Outlook

ASND

Earnings

Guidance Update

Product Launch

Ascendis Pharma reported total revenue of EUR 248 million for Q4 2025 and EUR 720 million for the full year 2025.
YORVIPATH revenue reached EUR 187 million in Q4 2025 and EUR 477 million for the full year, while SKYTROFA revenue was EUR 53 million in Q4 and EUR 206 million for the full year.
The company ended 2025 with EUR 616 million in cash and cash equivalents and projects operating cash flow of approximately EUR 500 million in 2026, with an aspiration for at least EUR 5 billion in annual product revenue by 2030.
Key regulatory milestones include the U.S. NDA for TransCon CNP remaining under review with a PDUFA date of February 28, and VISEN's approval of SKYTROFA in China in late January 2026.

Feb 11, 2026, 9:30 PM

Transcript

Ascendis Pharma Reports Q4 and Full-Year 2025 Results, Provides 2026 and 2030 Outlook

ASND

Earnings

Guidance Update

Product Launch

Ascendis Pharma reported Q4 2025 total revenue of EUR 248 million and full-year 2025 total revenue of EUR 720 million, driven by Europats revenue of EUR 187 million in Q4 and SKYTROFA revenue of EUR 53 million in Q4.
The company ended 2025 with EUR 616 million in cash and cash equivalents, and achieved Q4 2025 operating profit of EUR 10 million and operating cash flow of EUR 73 million.
Ascendis Pharma projects operating cash flow of approximately EUR 500 million in 2026 and aims for at least EUR 5 billion in annual product revenue by 2030.
The NDA for TransCon CNP in children with achondroplasia has a U.S. PDUFA date of February 28, with a regulatory decision in the EU expected in Q4 2026.

Feb 11, 2026, 9:30 PM

Transcript

Ascendis Pharma Provides Business Update at J.P. Morgan Healthcare Conference

ASND

Revenue Acceleration/Inflection

Guidance Update

Share Buyback

Ascendis Pharma reported strong financial performance with Q4 product revenue of approximately EUR 240 million and full-year revenue of approximately EUR 683 million.
The company projects significant future growth, targeting over EUR 5 billion in revenue by 2030, primarily driven by Yorvipath and Skytrofa.
Key upcoming milestones include the PDUFA date for TransCon CNP in February and a plan to buy back at least $120 million in shares this year.
Ascendis Pharma anticipates an operating cash flow of at least EUR 500 million and is expanding its European presence for Yorvipath with 10+ new countries expected in 2026.

Jan 12, 2026, 3:30 PM

Transcript

Highlights from the 44th J.P. Morgan Healthcare Conference

ASND

Guidance Update

Product Launch

New Projects/Investments

Ascendis Pharma (ASND) reported total full-year product revenue of $720 million for 2025, with Yorvipath contributing $477 million and SKYTROFA $206 million. The company anticipates TransCon CNP approval in Q1 2026 and plans a $120 million share buyback. Global peak sales expectations for Yorvipath are $5-$8 billion.
CRISPR Therapeutics highlighted its approved product Casgevy with multi-billion-dollar revenue potential and pipeline progress, including CTX310 for hypercholesterolemia, CTX611 (Factor XI siRNA) in Phase 2, and a 70% complete response rate for Zugocel (CAR-T) in oncology.
An unnamed company (Speaker 1) reported total net product revenue of $1.86 billion for FY 2025, including $899 million from Elevidys and $966 million from PMOs. The company ended 2025 with $954 million in cash and expects to be cash flow positive throughout the decade, with biomarker data for FSHD and DM1 programs expected by the end of Q1 2026.

Jan 12, 2026, 3:30 PM

Transcript

Companies Present Financial and Product Updates at J.P. Morgan Healthcare Conference

ASND

Revenue Acceleration/Inflection

Product Launch

Share Buyback

Ascendis Pharma reported Q4 product revenue of approximately EUR 240 million and full-year 2025 product revenue of about EUR 683 million, primarily from Yorvipath and Skytrofa, and aims for over EUR 5 billion in revenue by 2030. The company also plans to buy back at least $120 million in shares.
CRISPR Therapeutics announced that its approved product, Casgevy, has achieved over $100 million in revenue and shows strong momentum, with the company also highlighting CTX310 as a potential multi-billion-dollar opportunity in hypercholesterolemia.
Sarepta Therapeutics reported full-year 2025 total net product revenue of $1.86 billion, with Elevidys contributing $899 million (9% growth) and PMOs $966 million, ending the year with $954 million in cash and cash equivalents.

Jan 12, 2026, 3:30 PM

Transcript

Ascendis Pharma Reports 2025 Product Revenue and Outlines Vision 2030 Goals

ASND

Earnings

Guidance Update

Product Launch

Ascendis Pharma reported Q4 2025 product revenue of approximately €240 million and FY 2025 product revenue of approximately €683 million.
The company aims to achieve over €5 billion in annual revenue by 2030 as part of its Vision 2030 strategy, focusing on worldwide commercialization of its Endocrinology Rare Disease medicines.
Key product YORVIPATH® (TransCon PTH) generated approximately €477 million in FY 2025 revenue and is expanding commercially in over 30 countries.
SKYTROFA® (TransCon hGH) is approved for pediatric and adult growth hormone deficiency, with ongoing label and geographic expansion plans.
TransCon® CNP has an FDA PDUFA date of February 28, 2026, for achondroplasia, with an EU MAA decision anticipated in Q4 2026.

Jan 12, 2026, 3:30 PM

Presentation

Ascendis Pharma A/S Provides Business and Strategic Roadmap Update and Authorizes Share Repurchase Program

ASND

Guidance Update

New Projects/Investments

Share Buyback

Ascendis Pharma A/S provided a business and strategic roadmap update on January 9, 2026, outlining planned 2026 key corporate milestones.
Key regulatory updates include a U.S. PDUFA goal date of February 28, 2026, for TransCon CNP in pediatric achondroplasia, and an anticipated Q1 2026 approval decision from China's NMPA for TransCon hGH in pediatric growth hormone deficiency.
The company announced positive Week 52 topline results from the Phase 2 COACH Trial for TransCon CNP + TransCon hGH combination therapy on January 8, 2026, demonstrating improvements in annualized growth velocity and body proportionality.
The Board of Directors authorized a $120 million Share Repurchase Program.